Medclair AB (NGM:MCLR) Cyclically Adjusted Revenue per Share: kr0.48 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NGM:MCLR Medclair AB NGM:MCLR
70 GF Score
Price kr3.05
GF Value kr2.35
Valuation Modestly Overvalued
View Full Analysis

What is Medclair AB Cyclically Adjusted Revenue per Share?

Medclair AB NGM:MCLR -2.24% 70 Cyclically Adjusted Revenue per Share is kr0.48 as of Mar. 2026. GuruFocus rates NGM:MCLR with a GF Score™ of 70/100 and a GF Value™ of kr2.35 (Modestly Overvalued).

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Medclair AB's adjusted revenue per share data for the fiscal year that ended in Dec. 2025 was kr0.672. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is kr0.48 for the trailing ten years ended in Dec. 2025.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-07-15), Medclair AB's current stock price is kr 3.05. Medclair AB's Cyclically Adjusted Revenue per Share for the fiscal year that ended in Dec. 2025 was kr0.48. Medclair AB's Cyclically Adjusted PS Ratio of today is 6.35.

During the past 11 years, the highest Cyclically Adjusted PS Ratio of Medclair AB was 6.21. The lowest was 2.78. And the median was 4.06.


Medclair AB  (NGM:MCLR) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Medclair AB's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=3.05/0.48
=6.35

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 11 years, the highest Cyclically Adjusted PS Ratio of Medclair AB was 6.21. The lowest was 2.78. And the median was 4.06.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Medclair AB Cyclically Adjusted Revenue per Share Related Terms


Medclair AB Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Medclair AB's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medclair AB Cyclically Adjusted Revenue per Share Chart

Medclair AB Annual Data
Trend Apr16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.50 0.48

Medclair AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.48 0.00

NGM:MCLR vs ABT, SYK, MDT: Cyclically Adjusted Revenue per Share Comparison

For the Medical Devices subindustry, Medclair AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medclair AB Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Medclair AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Medclair AB's Cyclically Adjusted PS Ratio falls into.


NGM:MCLR
70GF Score
Medclair AB NGM:MCLR
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medclair AB Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Medclair AB's adjusted Revenue per Share data for the fiscal year that ended in Dec. 2025 was:

Adj_RevenuePerShare=Revenue per Share /CPI of Dec. 2025 (Change)*Current CPI (Dec. 2025)
=0.672/133.3900*133.3900
=0.672

Current CPI (Dec. 2025) = 133.3900.

Medclair AB Annual Data

Revenue per Share CPI Adj_RevenuePerShare
201604 0.239 100.732 0.316
201712 0.642 103.793 0.825
201812 0.594 105.912 0.748
201912 0.645 107.766 0.798
202012 0.075 108.296 0.092
202112 0.130 112.486 0.154
202212 0.299 126.365 0.316
202312 0.429 131.912 0.434
202412 0.485 132.987 0.486
202512 0.672 133.390 0.672

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of kr0.48 mean?
Medclair AB (NGM:MCLR) has a Cyclically Adjusted Revenue per Share of kr0.48 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Medclair AB and its competitors.
Is Medclair AB's Cyclically Adjusted Revenue per Share too high?
Medclair AB's current Cyclically Adjusted Revenue per Share is kr0.48. Overall, Medclair AB has a GF Score™ of 70/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medclair AB's Cyclically Adjusted Revenue per Share compare to ABT and SYK?
Medclair AB's Cyclically Adjusted Revenue per Share of kr0.48 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Medclair AB and its competitors. Medclair AB's current Cyclically Adjusted Revenue per Share is kr0.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medclair AB stock overvalued right now?
Based on GuruFocus' analysis, Medclair AB (NGM:MCLR) is currently considered Modestly Overvalued. The stock's GF Value™ is kr2.35, compared to a current price of kr3.05 — trading 29.8% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is kr0.48. Medclair AB's overall GF Score™ is 70/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Medclair AB (NGM:MCLR), the current Cyclically Adjusted Revenue per Share is kr0.48 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medclair AB (NGM:MCLR) Overvalued in 2026?

Based on GuruFocus' analysis, Medclair AB stock appears to be overvalued. The current stock price of kr3.05 is trading 29.8% above its estimated GF Value™ of kr2.35. GuruFocus considers Medclair AB to be Modestly Overvalued.

Key valuation signals for NGM:MCLR:

  • Cyclically Adjusted Revenue per Share: kr0.48
  • GF Value™: kr2.35 vs. price of kr3.05 (29.8% above fair value)
  • GF Score™: 70/100

No single metric tells the full story. See the NGM:MCLR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Medclair AB Business Description

Address Fraktflygargatan 1, Stockholm, SWE, 128 30
Medclair AB operates in healthcare industry. The company has two units: Central Destruction Unit (CDU) and Mobile Destruction Unit (MDU) decomposes the nitrous oxide entering the unit, transforming it to nitrogen (N2) och oxygen (O2). It also provide solutions for various N2O methods such as double mask, single mask, mouthpiece, or free flow, which ensures a safe work environment for healthcare professionals.
70GF Score

Get the complete analysis for NGM:MCLR

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr3.05
Price
kr2.35
GF Value